meningococcal ACWY 结合疫苗在青少年特发性关节炎和炎症性肠病患者中的免疫原性和安全性:一项前瞻性观察性队列研究
一项在荷兰开展的前瞻性观察性队列研究,纳入14-18岁JIA和IBD患者226例,接种MenACWY-TT疫苗后随访24个月。与健康对照相比,患者12个月时MenA和MenW的GMC较低;使用抗TNF药物的患者GMC更低,MenW保护比例降低。作者认为应考虑额外加强接种。
要点
- JIA和IBD青少年接种MenACWY结合疫苗后,MenA和MenW的GMC低于健康对照。
- 使用抗TNF药物的患者接种后MenACWY GMC更低,MenW保护比例(SBA≥8)为76% vs 非抗TNF者92% vs 健康对照100%。
- 作者建议考虑额外加强接种MenACWY疫苗。
核心结论
- MenACWY结合疫苗在大多数JIA和IBD青少年中具有免疫原性,但使用抗TNF药物的患者血清保护率较低,因此应考虑额外加强接种。
研究设计与样本
- 前瞻性观察性队列研究,纳入荷兰2018-2019年全国补种活动中接种MenACWY疫苗的14-18岁JIA和IBD患者226例(JIA 66%,IBD 34%),并与年龄匹配的健康对照数据比较。
主要发现
- 使用抗TNF药物的患者接种后MenACWY GMC低于未使用抗TNF者(p<0.01)。
- 接种后12个月,MenW保护比例(SBA≥8)在使用抗TNF者中为76%,非抗TNF者为92%,健康对照为100%(p<0.01)。
关键数值与推荐
- MenW保护比例(SBA≥8):抗TNF使用者76% vs 非抗TNF使用者92% vs 健康对照100%,p<0.01。
临床怎么用
- 作者认为,对于JIA和IBD青少年,MenACWY结合疫苗具有免疫原性,但使用抗TNF药物的患者血清保护率较低,应考虑额外加强接种MenACWY疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunogenicity to meningococcal serogroup ACWY (MenACWY) conjugate vaccine has not been studied in immunocompromised minors with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD). We determined immunogenicity of a MenACWY-TT vaccine in JIA and IBD patients at adolescent age and compared results to data from aged-matched healthy controls (HCs). METHODS: We performed a prospective observational cohort study in JIA and IBD patients (14-18 years old), who received a MenACWY vaccination during a nationwide catch-up campaign (2018-2019) in the Netherlands. Primary aim was to compare MenACWY polysaccharide-specific serum IgG geometric mean concentrations (GMCs) in patients with HCs and secondary between patients with or without anti-TNF therapy. GMCs were determined before and 3-6, 12, and 24 months postvaccination and compared with data from HCs at baseline and 12 months postvaccination. Serum bactericidal antibody (SBA) titers were determined in a subset of patients at 12 months postvaccination. RESULTS: We included 226 JIA and IBD patients (66 % and 34 % respectively). GMCs were lower for MenA and MenW (GMC ratio 0·24 [0·17-0·34] and 0·16 [0·10-0·26] respectively, p < 0·01) in patients compared to HCs at 12 months postvaccination. Anti-TNF users had lower MenACWY GMCs postvaccination compared with those without anti-TNF (p < 0·01). The proportion protected (SBA ≥ 8) for MenW was reduced in anti-TNF users (76 % versus 92 % in non-anti-TNF and 100 % in HCs, p < 0.01). CONCLUSION: The MenACWY conjugate vaccine was immunogenic in the vast majority of JIA and IBD patients at adolescent age, but seroprotection was lower in patients using anti-TNF agents. Therefore, an extra booster MenACWY vaccination should be considered.
引用
- Ohm M, van Straalen JW, Zijlstra M, et al. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study. Vaccine. 2023. PMID: 37198018. doi:10.1016/j.vaccine.2023.04.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。